Abstract

Background

p16 immunohistochemistry is used to evaluate for HPV-associated cervical intraepithelial neoplasia. The diagnostic performance of p16 in HIV infection is unclear.

Methods

Between June–December 2009, HIV-infected women underwent Papanicolaou (Pap) smear, human papillomavirus (HPV) testing, visual inspection with acetic acid (VIA), and colposcopy-directed biopsy as the disease gold standard at a HIV clinic in Kenya. Pap smears were evaluated for p16 expression. Sensitivity, specificity, positive predictive value (PPV), and area under the receiver operating characteristic curve (AUC) of p16 to detect CIN2/3 on histology and the impact of immunosuppression and ART was assessed.

Results

Of 331 cervical samples with p16 expression, p16 sensitivity and specificity to detect CIN2/3 was 54.1% and 72.4% respectively, which was lower than Pap and HPV in sensitivity, but higher in specificity than Pap, HPV, and VIA. Combining tests and p16 reduced sensitivity and increased specificity of Pap from 90.5% to 48.7% and 51.4% to 81.7%; of VIA from 59.5% to 37.8% and 67.6% to 89.9%; and of HPV from 82.4% to 50.0% and 55.3% to 84.8%. Combination p16 increased the PPV of Pap from 34.9% to 43.4%; of HPV from 34.7% to 48.7%; and VIA from 34.9% to 51.9%. Adjunctive p16 did not change AUC (P>0.05). P16 performance was not altered by immunosuppression or ART use. Combining p16 with HPV and VIA reduced the variation in HPV and VIA performance associated with CD4 and ART.
Conclusion

As an adjunctive test in HIV-infected women, p16 immunohistochemistry increased specificity and PPV of HPV and VIA for CIN2/3, and was not altered in performance by immunosuppression, ART, or age.

Introduction

Cervical cancer is one of the most prevalent cancers worldwide with the greatest burden among women in resource-limited settings [1]. Cervical neoplasm screening methods including Papanicolaou (Pap) smear, human papillomavirus (HPV) testing, and visual inspection with acetic acid (VIA) have dramatically reduced cervical cancer incidence and mortality [2, 3]. However, in resource-limited settings, cervical neoplasm screening is not routine and standard screening tools are not widely available [4]. Compared to HIV-uninfected women, the performance of existing cervical neoplasm screening methods may be less effective among HIV-infected women [5, 6].

HIV-infected women are disproportionately affected by HPV and at increased risk of developing HPV-associated cervical neoplasm and invasive cervical carcinoma [7, 8]. While HPV sensitivity has been shown to be high among HIV-infected women, HPV specificity is limited (55.7%) with further reductions associated with younger age, advanced immunosuppression, and shorter duration of antiretroviral therapy (ART) [5]. Similarly, VIA sensitivity was lower among older women and specificity varied by ART use [5]. Due to the elevated risk of cervical neoplasm in HIV-infected women, alternative screening strategies including biomarkers for cervical cancer precursors/intraepithelial may improve early detection and prevent invasive cervical carcinoma.

In HIV-uninfected women, p16 protein expression has been shown to distinguish mild cervical intraepithelial neoplasm (CIN1) from moderate to severe intraepithelial neoplasm (CIN2/3) with similar sensitivity but higher specificity for CIN2/3 than HPV testing [9, 10]. Moreover, the sensitivity and specificity of p16 in identifying intraepithelial neoplasia has been shown to be as high as 90% and 80%, respectively, in the general population [11–13]. There is limited data on the performance of p16 testing among HIV-infected women. An association between HIV infection and reduced p16 expression in CIN2/3 has been reported [14].

The objective of this study was to determine the performance of p16 immunohistochemistry to detect CIN2/3 among HIV-infected women while assessing the effect of immune status, ART use, and age, and to evaluate the utility of p16 staining alone and in combination with Pap smear, HPV, and VIA.

Methods

Study population and procedures

A total of 500 HIV-infected women were recruited from the Coptic Hope Center for Infectious Diseases in Nairobi, Kenya between June-December 2009. HIV-infected women were eligible for cervical screening if they were between ages 18 and 55 years, had an intact cervix, and never received treatment for cancerous or pre-cancerous cervical lesions. Methodology has been described elsewhere [5]. Demographic and clinical information was collected using standardized questionnaires and participants underwent pelvic examination and CD4 cell count. HIV history and ART use were abstracted from medical records. Women underwent Pap
smear and an endocervical brush collected for HPV. VIA was performed followed by colposcopy-directed biopsy. Pap and biopsy results were determined using Bethesda 1991 revised classification scheme and Richart CIN staging [15, 16]. Colposcopy-directed biopsy and its histology results were used as the gold standard for diagnosis.

Written informed consent was obtained from all study participants. Ethical approval was received by the University of Washington, Kenyatta National Hospital, and International Agency for Research on Cancer.

Laboratory methods

After Pap smears were read for cytology, slides were stored until shipment to Seattle, Washington to undergo p16 immunohistochemistry. After removing coverslips, the CINtec histology kit (Ventana Medical Systems, Inc. USA) was used to detect and stain for qualitative expression of p16 protein per manufacturer’s instructions [17]. Positive p16 protein was defined as the presence of any staining as compared to the absence of staining or p16 negative. HPV DNA typing was performed using GP5+/6+-mediated PCR with an enzyme immunoassay to detect 14 high-risk HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68). Positivity for any of these types was considered HPV positive [18].

Statistical methods

Disease was defined as the detection of CIN2/3 by colposcopy-directed biopsy on all women. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under the receiver operating characteristic curve (AUC) of abnormal Pap smear, defined as atypical squamous cells of undetermined significance or greater (≥ASCUS), HPV, and positive VIA were compared to the positive detection of p16 protein alone and in combination with other screening tests. Combinations included Pap with p16, HPV with p16, and VIA with p16. In these combinations, a positive screening result was defined as both tests being positive.

Comparisons of sensitivity and specificity were stratified by CD4 count (≤350 and >350 cells/μl), ART (none, <2 years and ≥2 years), and age (<40 and ≥40 years) and compared using chi-square tests. Statistical analyses were performed using STATA 13 (Stata Corporation, College Station, Texas, USA).

Results

Study population

Of 500 women screened, 471 had histology results, of which 331 (70.3%) cytology samples had adequate p16 results, 117 (24.8%) had indeterminate p16 results, and 23 (6.9%) were missing. Of the 331 women with p16 results, median age was 38.0 years and 80.7% were between ages 30–49 years. Forty percent were married and 34.7% reported one lifetime sexual partner. At screening, the median CD4 count was 371 cells/μl [Interquartile range (IQR), 249–544], 70% had CD4 ≤500 cells/μl and 52.4% had been on ART ≥2 years. There was no difference in age, CD4 count, or ART use between subjects with known results and those with indeterminate p16 results.

Cervical neoplasm screening

On histology, 125 (37.8%) were normal, 132 (39.9%) CIN1, 43 (13.0%) CIN2, and 31 (9.4%) CIN3. On Pap, 128 (38.7%) were normal, 56 (16.9%) ASCUS, 79 (23.9%) LSIL, 57 (17.2%) HSIL, and 11 (3.3%) indeterminate. On p16, 111 (33.5%) were positive; on Pap, 192 (58.0%)
were positive; on HPV, 176 (53.2%) were positive; and on VIA, 126 (38.5%) were positive. There was no difference in HPV, Pap, and histology between subjects with known results and subjects with indeterminate p16 results.

Sensitivity and specificity and associations with CD4 count, ART, and age

P16 sensitivity, specificity, PPV, NPV, and AUC were: 54.1%, 72.4%, 36.0%, 84.6%, and 0.63% (Table 1, Fig 1). Combining p16 with Pap reduced sensitivity and increased specificity and PPV from 90.5% to 48.7%, 51.4% to 81.7%, and 34.9% to 43.4%, respectively. Similarly, addition of p16 to HPV reduced sensitivity and increased specificity and PPV from 82.4% to 50.0%, 55.3% to 84.8%, and 34.7% to 48.7%. As an adjunct to VIA, p16 reduced sensitivity and increased specificity and PPV from 59.5% to 37.8%, 67.6% to 89.9%, and 33.9% to 51.9%. Combining tests with p16 did not significantly change the AUC (P > 0.05 for each method).

P16 performance was not altered by immune status, ART duration, or age at screening (Table 2). Sensitivity and specificity of p16 testing was similar at CD4 > 350 and > 350 cells/μl (51.4% vs. 56.8% and 69.9% vs. 74.3%, respectively) and among women < 40 years than ≥ 40 years (54.1% vs. 54.1% and 75.6% vs. 67.3%). While p16 sensitivity was higher among women on ART ≥ 2 years (62.2%) compared to women off ART (44.4%) and on ART < 2 years (47.4%), it was not statistically significant (P = 0.37). Similarly, p16 specificity did not differ by ART ≥ 2 years compared to no ART and ART < 2 years (71.3% vs. 75.0% vs. 70.8%, P = 0.83).

HPV specificity was higher at CD4 > 350 than ≤ 350 cells/μl (61.1% vs. 47.8%, P = 0.03), however, addition of p16 to HPV reduced this difference (86.8% vs. 82.3%, P = 0.32). Combining p16 with HPV reduced the difference in HPV specificity associated with ART ≥ 2 years

Table 1. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and area under the receiver operating characteristic curve (AUC) of screening methods individually and in combination with p16 to detect CIN2/3 (n = 331).

|               | CIN 2/3 (n = 74) | Sensitivity (95% CI) | Specificity (95% CI) | AUC (95% CI) | PPV (95% CI) | NPV (95% CI) |
|---------------|------------------|----------------------|----------------------|--------------|--------------|--------------|
| p16           |                  |                      |                      |              |              |              |
| Positive      | 40               | 54.1 (42.1–65.7)     | 72.4 (66.5–77.8)     | 0.63 (0.57–0.70) | 36.0 (27.1–45.7) | 84.6 (79.1–89.1) |
| Negative      | 34               |                      |                      |              |              |              |
| Pap (≥ ASCUS) |                  |                      |                      |              |              |              |
| Positive      | 67               | 90.5 (81.5–96.1)     | 51.4 (45.1–57.6)     | 0.71 (0.66–0.76) | 34.9 (28.2–42.1) | 95.0 (89.9–98.0) |
| Negative      | 7                |                      |                      |              |              |              |
| Pap (≥ ASCUS) and p16 |      |                      |                      |              |              |              |
| Positive      | 36               | 48.7 (36.9–60.6)     | 81.7 (76.4–86.2)     | 0.65 (0.59–0.71) | 43.4 (32.5–54.7) | 84.7 (79.6–88.9) |
| Negative      | 38               |                      |                      |              |              |              |
| VIA           |                  |                      |                      |              |              |              |
| Positive      | 44               | 59.5 (47.4–70.7)     | 67.6 (61.4–73.3)     | 0.64 (0.57–0.70) | 34.9 (26.6–43.9) | 85.1 (79.4–89.7) |
| Negative      | 30               |                      |                      |              |              |              |
| VIA and p16   |                  |                      |                      |              |              |              |
| Positive      | 28               | 37.8 (26.8–49.9)     | 89.9 (85.5–93.3)     | 0.64 (0.58–0.70) | 51.9 (37.8–65.7) | 83.4 (78.5–87.6) |
| Negative      | 46               |                      |                      |              |              |              |
| HPV           |                  |                      |                      |              |              |              |
| Positive      | 61               | 82.4 (71.8–90.3)     | 55.3 (49.0–61.4)     | 0.69 (0.64–0.74) | 34.7 (27.7–42.2) | 91.6 (86.1–95.5) |
| Negative      | 13               |                      |                      |              |              |              |
| HPV and p16   |                  |                      |                      |              |              |              |
| Positive      | 37               | 50.0 (38.1–61.9)     | 84.8 (79.8–89.0)     | 0.67 (0.61–0.74) | 48.7 (37.0–60.4) | 85.5 (80.6–89.6) |
| Negative      | 37               |                      |                      |              |              |              |
versus no ART and ART < 2 years (61.8% vs. 48.6% and 45.8%, P = 0.07 for HPV and 86.0% vs. 84.7% and 81.3%, P = 0.73 for combination HPV and p16), and younger vs. older age (48.1% vs. 66.3%, P = 0.004 for HPV and 84.0% and 86.1%, P = 0.64 for combination HPV and p16). Adjunct p16 testing reduced the variability in VIA sensitivity associated with age (75.7% in < 40 years vs. 43.2% ≥ 40 years, P = 0.004 for VIA and 45.9% vs. 29.7%, P = 0.15 for VIA and p16) and the differences in VIA specificity associated with ≥ 2 years ART vs. no ART and < 2 years ART (75.2% vs. 63.9% and 51.1%, P = 0.007 for VIA and 92.7% vs. 90.3% and 81.3%, P = 0.08 for VIA and p16).

**Discussion**

Among HIV-infected women, the use of p16 for the detection of histologically confirmed CIN2/3 had higher specificity (72.4%) and lower sensitivity (54.1%) compared to Pap, VIA, and HPV. While the performance of p16 alone was comparable to VIA, p16 sensitivity was markedly lower than HPV and Pap (≥ ASCUS) and AUC was comparable between methods. As an adjunctive screening test for cervical neoplasia among HIV-infected women, p16 decreased sensitivity but increased specificity and PPV and its performance was not altered by immune status, ART duration, and age at screening.

P16 protein expression as a screening method and adjunct test among HIV-infected women is not well documented. Studies of p16 in HIV-negative women have shown sensitivity from 79–97%, specificity from 71–85%, and PPV from 41–91% [10, 19–21]. In our population of HIV-infected women, p16 sensitivity (54%), specificity (72%), and PPV (36%) were lower, irrespective of ART and immune status. This is in agreement with a study showing decreased p16 expression in HIV-infected women with CIN2/3 compared to their HIV-uninfected counterparts [14]. While our results do not support p16 testing alone, as an adjunctive test p16 increased the PPV of Pap, HPV, and VIA. Expression of p16 protein is associated with HPV integration and increases from no expression in normal tissue to overexpression in cervical intraepithelial neoplasia and carcinoma [22–24]. As a potential marker of progression, p16 positive lesions may therefore be important precancerous/intraepithelial neoplasms to treat.
Table 2. Sensitivity and specificity of screening methods to detect CIN2/3 compared by CD4 count (A), ART duration (B), and age at screening (C) (n = 331).

|                | CD4 ≤350 | CD4 >350 | P-value |
|----------------|----------|----------|---------|
| **Sensitivity**|          |          |         |
| A) CD4 count   |          |          |         |
| p16            | 51.4     | 56.8     | 0.64    |
| Pap (≥ASCUS)   | 91.9     | 89.2     | 0.69    |
| Pap (≥ASCUS) and p16 | 54.1     | 43.2     | 0.35    |
| VIA            | 64.9     | 54.1     | 0.34    |
| VIA and p16    | 35.1     | 40.5     | 0.63    |
| HPV            | 81.1     | 83.8     | 0.76    |
| HPV and p16    | 43.2     | 56.8     | 0.25    |
| **Specificity**|          |          |         |
| n = 37 CIN2/3  |          |          |         |
| p16            | 69.9     | 74.3     | 0.43    |
| Pap (≥ASCUS)   | 48.7     | 53.5     | 0.45    |
| Pap (≥ASCUS) and p16 | 80.5     | 82.6     | 0.66    |
| VIA            | 64.9     | 69.7     | 0.41    |
| VIA and p16    | 86.7     | 92.4     | 0.14    |
| HPV            | 47.8     | 61.1     | 0.03    |
| HPV and p16    | 82.3     | 86.8     | 0.32    |
| Specificity    | n = 113 ≤CIN1 | n = 144 ≤CIN1 | |
| n = 37 CIN2/3  |          |          |         |
| p16            | 60.3     | 72.9     | 0.43    |
| Pap (≥ASCUS)   | 47.5     | 53.5     | 0.45    |
| Pap (≥ASCUS) and p16 | 78.7     | 82.6     | 0.66    |
| VIA            | 65.0     | 69.7     | 0.41    |
| VIA and p16    | 85.7     | 92.4     | 0.14    |
| HPV            | 48.6     | 61.1     | 0.03    |
| HPV and p16    | 83.6     | 86.8     | 0.32    |
| **Sensitivity**| Off ART | On ART <2 years | On ART ≥2 years | P-value |
| n = 18 CIN2/3  |          |          |          |         |
| n = 37 CIN2/3  |          |          |          |         |
| p16            | 44.4     | 47.4     | 62.2     | 0.37    |
| Pap (≥ASCUS)   | 94.4     | 94.7     | 86.5     | 0.49    |
| Pap (≥ASCUS) and p16 | 44.4     | 47.4     | 51.4     | 0.88    |
| VIA            | 50.0     | 63.2     | 62.2     | 0.64    |
| VIA and p16    | 33.3     | 31.6     | 43.2     | 0.63    |
| HPV            | 88.9     | 78.9     | 81.1     | 0.70    |
| HPV and p16    | 44.4     | 36.8     | 59.5     | 0.24    |
| Specificity    | n = 72 ≤CIN1 | n = 48 ≤CIN1 | n = 136 ≤CIN1 | |
| n = 37 CIN2/3  |          |          |          |         |
| n = 37 CIN2/3  |          |          |          |         |
| p16            | 75.0     | 70.8     | 71.3     | 0.83    |
| Pap (≥ASCUS)   | 52.8     | 45.8     | 52.2     | 0.71    |
| Pap (≥ASCUS) and p16 | 83.3     | 79.2     | 81.6     | 0.85    |
| VIA            | 63.9     | 51.1     | 75.2     | 0.007   |
| VIA and p16    | 90.3     | 81.3     | 92.7     | 0.08    |
| HPV            | 48.6     | 45.8     | 61.8     | 0.07    |
| HPV and p16    | 84.7     | 81.3     | 86.0     | 0.73    |
| Sensitivity    | Age <40 years | Age ≥40 years | P-value |
| n = 37 CIN2/3  |          |          |         |
| n = 37 CIN2/3  |          |          |         |
| p16            | 54.1     | 54.1     | 1.00    |
| Pap (≥ASCUS)   | 91.9     | 89.2     | 0.69    |
| Pap (≥ASCUS) and p16 | 51.4     | 46.0     | 0.64    |
| VIA            | 75.7     | 43.2     | 0.004   |
| VIA and p16    | 45.9     | 29.7     | 0.15    |
| HPV            | 78.4     | 86.5     | 0.36    |

(Continued)
This is of particular relevance in settings where other triage methods including colposcopy directed-biopsy are less readily available.

The effect of immunosuppression and ART on the performance of cervical neoplasia tests in HIV-infected women has been documented [5, 6]. Unlike these other screening tests, the sensitivity and specificity of p16 was not influenced by HIV-associated immunosuppression, ART duration, or age. Moreover, adjunctive p16 testing removed the associations between HPV sensitivity and specificity and CD4 count and little or no ART. U.S. guidelines recommend HPV testing for primary cervical cancer screening followed by cytology or colposcopy among HPV-positive women [25]. In HIV-endemic settings, World Health Organization (WHO) recommendations include HPV testing followed by VIA to determine eligibility for treatment if HPV positive [26]. As HIV-infected women are at increased risk of HPV-associated disease, adjunctive p16 testing may help to discriminate between transient HPV infections and precancerous lesions/intraepithelial neoplasia, reducing overtreatment.

A major strength of this study is the use of colposcopy-directed biopsy on all women. As a result, our findings may better reflect p16 sensitivity in combination with other cervical neoplasia screening methods. In addition, this study included detailed data on CD4 count and ART exposure. However, this study has several limitations. P16 staining was performed on archived samples, of which 24.8% had indeterminate results. Sensitivity analysis showed that there was no difference between subjects with indeterminate and determinate p16 results by sociodemographic characteristics, clinical factors, or CIN2/3. The use of archived samples may have reduced quality due to long-term storage and the de-staining and re-staining procedures. Cell loss may have occurred during the removal of plastic coverslips, reducing p16 interpretability. Additional studies are needed to investigate p16 staining on cytology samples without prior staining. This study did not use positive p16 control slides to ensure internal quality assurance and this may limit interpretability of our results. Finally, while we had detailed data on immune status and ART duration, we did not have longitudinal data related to the duration of immunosuppression, HIV diagnosis date, and progression or persistence of cervical lesions/neoplasm.

As an adjunctive test to HPV and VIA in HIV-infected women, p16 increased specificity and PPV and reduced the variation in HPV and VIA performance associated with immunosuppression and ART duration. As WHO and U.S. guidelines recommend HPV genotyping as the primary screening for referral and treatment, adjunctive p16 testing may reduce unnecessary colposcopy and subsequent overtreatment among HIV-infected women.

Supporting information

S1 File. P16 Dataset. p16_PlosOne.xls.
(XLS)
Author Contributions

**Conceptualization:** Christine J. McGrath, Grace C. John-Stewart, Nelly R. Mugo, Hugo De Vuyst, Michael H. Chung.

**Data curation:** Rochelle Garcia, Emily H. Glynn.

**Formal analysis:** Christine J. McGrath, Barbra A. Richardson.

**Funding acquisition:** Michael H. Chung.

**Investigation:** Grace C. John-Stewart, Evans Nyongesa-Malava, Hugo De Vuyst, Michael H. Chung.

**Methodology:** Christine J. McGrath, Rochelle Garcia, Trong T. Trinh, Barbra A. Richardson, Grace C. John-Stewart, Nelly R. Mugo, Emily H. Glynn, Hugo De Vuyst, Michael H. Chung.

**Project administration:** Trong T. Trinh, Evans Nyongesa-Malava.

**Resources:** Samah R. Sakr.

**Supervision:** Evans Nyongesa-Malava, Nelly R. Mugo, Michael H. Chung.

**Validation:** Christine J. McGrath, Rochelle Garcia, Barbra A. Richardson.

**Writing – original draft:** Christine J. McGrath, Hugo De Vuyst, Michael H. Chung.

**Writing – review & editing:** Christine J. McGrath, Rochelle Garcia, Trong T. Trinh, Barbra A. Richardson, Grace C. John-Stewart, Evans Nyongesa-Malava, Nelly R. Mugo, Emily H. Glynn, Samah R. Sakr, Hugo De Vuyst, Michael H. Chung.

References

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. *CA Cancer J Clin* 2011, 61:69–90. https://doi.org/10.3322/caac.20107 PMID: 21296855

2. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer* 2015, 136: E359–386. https://doi.org/10.1002/ijc.29210 PMID: 25220842

3. de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. *Int J Cancer* 2017, 141:664–670. https://doi.org/10.1002/ijc.30716 PMID: 28369882

4. Santesso N, Mustafa RA, Schunemann HJ, Arbyn M, Blumenthal PD, Cain J, et al. World Health Organization Guidelines for treatment of cervical intraepithelial neoplasia 2–3 and screen-and-treat strategies to prevent cervical cancer. *Int J Gynaecol Obstet* 2016, 132:252–258. https://doi.org/10.1016/j.ijgo.2015.07.038 PMID: 26868062

5. Chung MH, McKenzie KP, De Vuyst H, Richardson BA, Rana F, Pamnnari R, et al. Comparing pap smear, via, and HPV cervical cancer screening methods among HIV-positive women by immune status and antiretroviral therapy. *AIDS* 2013.

6. Finnhaber C, Maysela N, Mao L, Williams S, Swarts A, Faesen M, et al. Validation of cervical cancer screening methods in HIV positive women from Johannesburg South Africa. *Plos One* 2013, 8: e53494. https://doi.org/10.1371/journal.pone.0053494 PMID: 23326441

7. De Vuyst H, Lillo F, Brouet N, Smith JS. HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. *Eur J Cancer Prev* 2008, 17:545–554. https://doi.org/10.1097/CEJ.0b013e3282f55e1 PMID: 18941376

8. Clifford GM, Gonzales MA, Franceschi S, HPV, Group HIVS. Human papillomavirus types among women infected with HIV: a meta-analysis. *AIDS 2006*, 20:2337–2344. https://doi.org/10.1097/01.aids.0000253636.63578.14 PMID: 17117020

9. Zhong P, Li J, Gu Y, Liu Y, Wang A, Sun Y, et al. P16 and Ki-67 expression improves the diagnostic accuracy of cervical lesions but not predict persistent high risk human papillomavirus infection with CIN1. *Int J Clin Exp Pathol* 2015, 8:2979–2986. PMID: 26045907
10. Samarawardana P, Dehn DL, Singh M, Franquemont D, Thompson C, Gaido L, et al. p16(INK4a) is superior to high-risk human papillomavirus testing in cervical cytology for the prediction of underlying high-grade dysplasia. *Cancer Cytopathol* 2010, 118:146–156. https://doi.org/10.1002/cncy.20078 PMID: 20544710

11. Zhang G, Yang B, Abdul-Karim FW. p16 Immunohistochemistry is useful in confirming high-grade squamous intraepithelial lesions (HSIL) in women with negative HPV testing. *Int J Gynecol Pathol* 2015, 34:180–186. https://doi.org/10.1097/PGP.0000000000000112 PMID: 25675189

12. Yildiz IZ, Usubutun A, Firat P, Ayhan A, Kucukali T. Efficiency of immunohistochemical p16 expression and HPV typing in cervical squamous intraepithelial lesion grading and review of the p16 literature. *Pathol Res Pract* 2007, 203:445–449. https://doi.org/10.1016/j.prp.2007.03.010 PMID: 17543474

13. Tsoumpou I, Arbyn M, Kyrgiou M, Wentzensen N, Koliopoulos G, Martin-Hirsch P, et al. p16(INK4a) immunostaining in cytological and histological specimens from the uterine cervix: a systematic review and meta-analysis. *Cancer Treat Rev* 2009, 35:210–220. https://doi.org/10.1016/j.ctrv.2008.10.005 PMID: 19261387

14. Nicol AF, Golub JE, e Silva JR, Cunha CB, Amaro-Filho SM, Oliveira NS, et al. An evaluation of p16 (INK4a) expression in cervical intraepithelial neoplasia specimens, including women with HIV-1. *Mem Inst Oswaldo Cruz* 2012, 107:571–577. PMID: 22850945

15. Luff RD. The Bethesda System for reporting cervical/vaginal cytologic diagnoses. Report of the 1991 Bethesda workshop. *Am J Clin Pathol* 1992, 98:152–154. PMID: 1354939

16. Richard RM. Cervical intraepithelial neoplasia. *Pathol Annu* 1973, 8:301–328. PMID: 4583016

17. Roche Diagnostics International Ltd. CInTec p16 Cervical histology: Compendium and Staining Atlas. In: 2013.

18. De Vuyst H, Mugo NR, Chung MH, McKenzie KP, Nyongesa-Malava E, Tenet V, et al. Prevalence and determinants of human papillomavirus infection and cervical lesions in HIV-positive women in Kenya. *Br J Cancer* 2012, 107:1624–1630. https://doi.org/10.1038/bjc.2012.441 PMID: 23033006

19. de Melo FL, Lancellotti CL, da Silva MA. Expression of the Immunohistochemical Markers p16 and Ki-67 and Their Usefulness in the Diagnosis of Cervical Intraepithelial Neoplasms. *Rev Bras Ginecol Obstet* 2016, 38:82–87. https://doi.org/10.1055/s-0036-1571470 PMID: 26883858

20. Denton KJ, Bergeron C, Clement P, Trunk MJ, Keller T, Ridder R, et al. The sensitivity and specificity of p16(INK4a) cytolgoy vs HPV testing for detecting high-grade cervical disease in the triage of ASC-US and LSIL pap cytology results. *Am J Clin Pathol* 2010, 134:12–21. https://doi.org/10.1309/AJCP3CD9KFFJQDM PMID: 20551261

21. Guo M, Baruch AC, Silva EG, Jan YJ, Lin E, Sneige N, et al. Efficacy of p16 and ProExC immunostaining in the detection of high-grade cervical intraepithelial neoplasia and cervical carcinoma. *Am J Clin Pathol* 2011, 135:212–220. https://doi.org/10.1309/AJCP1LLX8QMDXHHO PMID: 21228361

22. Alshenawy HA. Evaluation of p16, human papillomavirus capsid protein L1 and Ki-67 in cervical intraepithelial lesions: potential utility in diagnosis and prognosis. *Pathol Res Pract* 2014, 210:916–921. https://doi.org/10.1016/j.prp.2014.07.007 PMID: 25149503

23. Arvizo C, Chen Q, Du H, Wang C, Tang J, Yang B, et al. p16 Immunohistochemistry in Colposcopic-Directed and Random Cervical Biopsies of CIN2 and CIN3. *J Low Genit Tract Dis* 2016

24. Lee H, Lee EJ. HPV infection and p16 promoter methylation as predictors of ASC-US/LSIL progression. *Cancer Cytopathol* 2016, 124:58–65. https://doi.org/10.1002/cncy.21615 PMID: 26335500

25. US Food and Drug Administration. FDA approves first human papillomavirus test for primary cervical cancer screening. In: 2014.

26. World Health Organization. WHO guidelines for screening and treatment of precancerous lesions for cervical cancer prevention. In. Geneva, Switzerland: WHO Press; 2013.